Immunosin (Inosine Pranobex) Dosing
The recommended dose of Immunosin (inosine pranobex) tablets for adults is 4 capsules (2000 mg) once daily, or alternatively 50 mg/kg body weight per day divided into 3-4 doses (maximum 4 g/day), typically given as 1 gram three times daily. 1
Standard Adult Dosing
The FDA-approved labeling specifies 4 capsules once daily as the usual adult dose 1. However, clinical research consistently demonstrates that the most commonly studied and effective regimen is:
- 50 mg/kg body weight per day (rounded to nearest 500 mg)
- Maximum daily dose: 4 grams
- Divided into 3-4 doses throughout the day
- Typical regimen: 1 gram (two 500 mg tablets) three times daily 2, 3, 4
Duration of Treatment
Treatment duration varies by indication:
- Acute viral infections (COVID-19): 10 days 2
- HIV infection: 24 weeks (6 months) in clinical trials 3
- HPV/genital warts: 4-6 weeks 4, 5
- Chronic viral conditions: May require extended therapy based on clinical response 6
Pediatric Dosing
While the provided evidence focuses primarily on adult dosing, the weight-based calculation of 50 mg/kg/day can be applied to pediatric patients, with appropriate rounding to the nearest 500 mg dose and the same 4 gram maximum daily limit 2.
Important Clinical Considerations
Timing of administration: The drug should be started early in viral infections to maximize benefit, as inosine pranobex enhances natural killer cell activity as an early immune response 2. For COVID-19 specifically, initiation during mild-to-moderate disease showed significantly better outcomes than delayed treatment 2.
Administration: Can be taken with or without food. The divided dosing schedule (3-4 times daily) is preferred over once-daily dosing in most clinical studies, though the FDA label mentions once-daily as an option 1, 2, 3.
Safety profile: The medication demonstrates excellent tolerability with minimal adverse effects. Studies report mild, self-limiting reactions in approximately 2-4% of patients, primarily gastrointestinal symptoms or skin rash 4, 6. No serious adverse effects or mortality were attributed to the drug in large-scale studies 2, 7.
Pregnancy: The FDA label advises consulting a healthcare professional if pregnant or nursing 1, and the medication is available by prescription only 1.